VeinWay
Or Yehuda, Israel· Est.
VeinWay creates a first‑of‑its‑kind catheter to quickly cross chronic venous occlusions, addressing an unmet need in vascular medicine.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
VeinWay creates a first‑of‑its‑kind catheter to quickly cross chronic venous occlusions, addressing an unmet need in vascular medicine.
VascularVenous Disease
Technology Platform
A nitinol‑based catheter system (Traversa) that uses a proprietary crossing tip and torque control to navigate and recanalize chronic venous occlusions quickly and safely.
Opportunities
A clear unmet need for reliable crossing of chronic venous occlusions creates a large market for a device that can reduce procedure time and improve patency rates.
Risk Factors
Regulatory approval and demonstration of clinical superiority over existing guidewires are critical; adoption may be slowed by physician familiarity with entrenched technologies.
Competitive Landscape
Current competitors include Medtronic, Boston Scientific, and Philips, which offer conventional guidewires and atherectomy tools; VeinWay differentiates itself with a dedicated crossing catheter designed for previously uncrossable veins.